person · Reporting owner

Teehan Brendan

Disclosed activity across 2 companies

Tapewire entity: 66467
SEC CIK: 0001891900

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Pacira BioSciences, Inc.PCRX · Entity 4928	Chief Commercial Officer	February 11, 2026	February 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Pacira BioSciences, Inc.

Report date February 11, 2026 · Filed February 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	100,934.268	Reported balance After 2026-02-11 transaction · row 1 1 source row Row 1 · 2026-02-11 · Grant · Acquired 51,714 · Balance 100,934.268 F1: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACADIA PHARMACEUTICALS INC

Report date November 17, 2024 · Filed November 20, 2024

Section 16 reporting ended · disclosed 2024-11-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	62,521	Reported balance After 2024-11-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-11-17 · Exercise / conversion · Acquired 9,913 · Balance 62,521 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2: Includes 431 shares of the Issuer's common stock acquired by the reporting person on November 15, 2024 pursuant to an employee stock purchase plan.
Common StockSEC Table I · non-derivative	Direct	72,434	Reported balance After 2024-11-17 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2024-11-17 · Exercise / conversion · Acquired 9,913 · Balance 72,434 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Common StockSEC Table I · non-derivative	Direct	62,105	Reported balance After 2024-11-19 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2024-11-19 · Sale · Disposed 10,329 · Balance 62,105 F3: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7947 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	9,913	Reported balance After 2024-11-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-11-17 · Exercise / conversion · Disposed 9,913 · Balance 9,913 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	9,913	Reported balance After 2024-11-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-11-17 · Exercise / conversion · Disposed 9,913 · Balance 9,913 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2: Includes 431 shares of the Issuer's common stock acquired by the reporting person on November 15, 2024 pursuant to an employee stock purchase plan.

F3: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7947 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F5: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F6: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 11, 2026 Filed Feb 13, 2026 21:02 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	51,714	$0.00	$0.00	Disclosure SEC source: 0001628280-26-008077 · wk-form4_1771016527.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,934.268 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
January 30, 2026 Filed Feb 3, 2026 23:23 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Tax withholdingCommon Stock	5,182	$20.54	$106,438.28	Disclosure SEC source: 0001628280-26-005154 · wk-form4_1770161023.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,220.268 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document
December 31, 2025 Filed Jan 6, 2026 22:30 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	402.268	$10.76	$4,329.61	Disclosure SEC source: 0001628280-26-000964 · wk-form4_1767738624.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,402.268 F1 · shares: Represents shares of common stock acquired under the issuer's employee stock purchase plan in December 2025. Read SEC document
February 04, 2025 Filed Feb 4, 2025 23:25 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	99,500	$26.59 Strike: $26.59	$2,645,705.00	Disclosure SEC source: 0001396814-25-000030 · wk-form4_1738711527.xml · derivative · entry 2 Teehan Brendan · CIK 0001891900 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,500 Underlying: Common Stock · 99,500 shares Expires 2036-02-04 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document
February 01, 2025 Filed Feb 4, 2025 23:25 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	54,000	$0.00	$0.00	Disclosure SEC source: 0001396814-25-000030 · wk-form4_1738711527.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 1, 2026, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
November 19, 2024 Filed Nov 20, 2024 01:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	10,329	$16.81	$173,630.49	Disclosure SEC source: 0001415889-24-027294 · form4-11202024_011138.xml · nonDerivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,105 F3 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7947 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	9,913	$0.00	$0.00	Disclosure SEC source: 0001415889-24-027294 · form4-11202024_011138.xml · derivative · entry 5 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,913 Underlying: Common Stock · 9,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F6 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	9,913	$0.00	$0.00	Disclosure SEC source: 0001415889-24-027294 · form4-11202024_011138.xml · derivative · entry 4 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,913 Underlying: Common Stock · 9,913 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	9,913	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-027294 · form4-11202024_011138.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	9,913	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-027294 · form4-11202024_011138.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 431 shares of the Issuer's common stock acquired by the reporting person on November 15, 2024 pursuant to an employee stock purchase plan. Read SEC document
August 19, 2024 Filed Aug 20, 2024 22:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	9,534	$15.28	$145,679.52	Disclosure SEC source: 0001415889-24-021726 · form4-08202024_100820.xml · nonDerivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,177 F4 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 16, 2024 Filed Aug 20, 2024 22:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantCommon Stock	13,629	$0.00	$0.00	Disclosure SEC source: 0001415889-24-021726 · form4-08202024_100820.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,711 F3 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target. Read SEC document
August 16, 2024 Filed Aug 20, 2024 22:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantCommon Stock	5,024	$0.00	$0.00	Disclosure SEC source: 0001415889-24-021726 · form4-08202024_100820.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,082 F1 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target. F2 · balance_after: Includes 925 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024. Read SEC document
May 02, 2024 Filed May 3, 2024 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	3,477	$16.94	$58,900.38	Disclosure SEC source: 0001415889-24-012239 · form4-05032024_060515.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,133 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.94 to $17.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
May 01, 2024 Filed May 3, 2024 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	6,814	$0.00	$0.00	Disclosure SEC source: 0001415889-24-012239 · form4-05032024_060515.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,445 Underlying: Common Stock · 6,814 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. Read SEC document
May 01, 2024 Filed May 3, 2024 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	6,814	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-012239 · form4-05032024_060515.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
April 08, 2024 Filed Apr 9, 2024 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	2,568	$17.87	$45,890.16	Disclosure SEC source: 0001415889-24-010603 · form4-04092024_060407.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,796 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.7875 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
April 05, 2024 Filed Apr 9, 2024 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	5,024	$0.00	$0.00	Disclosure SEC source: 0001415889-24-010603 · form4-04092024_060407.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,048 Underlying: Common Stock · 5,024 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document
April 05, 2024 Filed Apr 9, 2024 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	5,024	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-010603 · form4-04092024_060407.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
March 27, 2024 Filed Mar 28, 2024 00:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	5,140	$17.90	$92,006.00	Disclosure SEC source: 0001415889-24-009272 · form4-03272024_110355.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,340 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
March 25, 2024 Filed Mar 28, 2024 00:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	27,460	$0.00	$0.00	Disclosure SEC source: 0001415889-24-009272 · form4-03272024_110355.xml · derivative · entry 4 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,460 Underlying: Common Stock · 27,460 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025. Read SEC document
March 25, 2024 Filed Mar 28, 2024 00:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantStock Options (Right to Buy) · Derivative	89,516	$0.00 Strike: $17.84	$0.00	Disclosure SEC source: 0001415889-24-009272 · form4-03272024_110355.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,516 Underlying: Common Stock · 89,516 shares Expires 2034-03-24 F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
March 25, 2024 Filed Mar 28, 2024 00:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantCommon Stock	10,048	$0.00	$0.00	Disclosure SEC source: 0001415889-24-009272 · form4-03272024_110355.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,480 F1 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target. Read SEC document
February 26, 2024 Filed Feb 27, 2024 23:10 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	624	$24.67	$15,394.08	Disclosure SEC source: 0001415889-24-005575 · form4-02272024_110225.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,432 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
February 23, 2024 Filed Feb 27, 2024 23:10 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	1,107	$0.00	$0.00	Disclosure SEC source: 0001415889-24-005575 · form4-02272024_110225.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,107 Underlying: Common Stock · 1,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. Read SEC document
February 23, 2024 Filed Feb 27, 2024 23:10 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	1,107	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-005575 · form4-02272024_110225.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, HEAD OF COMMERCIAL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
January 08, 2024 Filed Jan 9, 2024 23:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	731	$29.96	$21,900.76	Disclosure SEC source: 0001209191-24-001268 · doc4.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,949 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.61 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 06, 2024 Filed Jan 9, 2024 23:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	1,287	$0.00	$0.00	Disclosure SEC source: 0001209191-24-001268 · doc4.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,287 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. F4 · derivative.expiration_date: One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. Read SEC document
January 06, 2024 Filed Jan 9, 2024 23:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	1,287	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001268 · doc4.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document
November 20, 2023 Filed Nov 21, 2023 23:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	4,960	$22.64	$112,294.40	Disclosure SEC source: 0001209191-23-056355 · doc4.xml · nonDerivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,393 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.64 to $22.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	4,956	$0.00	$0.00	Disclosure SEC source: 0001209191-23-056355 · doc4.xml · derivative · entry 5 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,826 Underlying: Common Stock · 4,956 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F6 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	4,956	$0.00	$0.00	Disclosure SEC source: 0001209191-23-056355 · doc4.xml · derivative · entry 4 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,826 Underlying: Common Stock · 4,956 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	4,956	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-056355 · doc4.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
November 17, 2023 Filed Nov 21, 2023 23:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	4,956	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-056355 · doc4.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 707 and 378 shares of the Issuer's common stock acquired by the reporting person on May 15, 2023 and November 15, 2023, respectively, pursuant to an employee stock purchase program. Read SEC document
May 17, 2023 Filed May 19, 2023 22:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	14,869	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031241 · doc4.xml · derivative · entry 5 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,782 Underlying: Common Stock · 14,869 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F4 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document
May 17, 2023 Filed May 19, 2023 22:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	14,869	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031241 · doc4.xml · derivative · entry 4 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,782 Underlying: Common Stock · 14,869 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document
May 17, 2023 Filed May 19, 2023 22:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	14,869	$22.50	$334,552.50	Disclosure SEC source: 0001209191-23-031241 · doc4.xml · nonDerivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,356 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document
May 17, 2023 Filed May 19, 2023 22:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	14,869	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-031241 · doc4.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document
May 17, 2023 Filed May 19, 2023 22:43 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	14,869	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-031241 · doc4.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document
May 01, 2023 Filed May 2, 2023 23:04 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	548	$21.18	$11,606.64	Disclosure SEC source: 0001209191-23-026744 · doc4.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,487 F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document
May 01, 2023 Filed May 4, 2023 01:17 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	27,259	$0.00	$0.00	Disclosure SEC source: 0001209191-23-027207 · doc4.xml · derivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,259 Underlying: Common Stock · 27,259 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. Read SEC document
May 01, 2023 Filed May 4, 2023 01:17 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantStock Options (Right to Buy) · Derivative	89,936	$0.00 Strike: $21.75	$0.00	Disclosure SEC source: 0001209191-23-027207 · doc4.xml · derivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,936 Underlying: Common Stock · 89,936 shares Expires 2033-05-01 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
April 29, 2023 Filed May 2, 2023 23:04 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	1,567	$0.00	$0.00	Disclosure SEC source: 0001209191-23-026744 · doc4.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023. F3 · derivative.expiration_date: 50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023. Read SEC document
April 29, 2023 Filed May 2, 2023 23:04 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	1,567	$0.00	$0.00	Disclosure SEC source: 0001209191-23-026744 · doc4.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 06, 2023 Filed Apr 8, 2023 00:44 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	1,751	$18.16	$31,798.16	Disclosure SEC source: 0001209191-23-023865 · doc4.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,468 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document
April 05, 2023 Filed Apr 8, 2023 00:44 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	5,024	$0.00	$0.00	Disclosure SEC source: 0001209191-23-023865 · doc4.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,072 Underlying: Common Stock · 5,024 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document
April 05, 2023 Filed Apr 8, 2023 00:44 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	5,024	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-023865 · doc4.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document
February 24, 2023 Filed Feb 28, 2023 02:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	461	$18.78	$8,657.58	Disclosure SEC source: 0001209191-23-013468 · doc4.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,195 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document
February 23, 2023 Filed Feb 28, 2023 02:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	1,107	$0.00	$0.00	Disclosure SEC source: 0001209191-23-013468 · doc4.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,214 Underlying: Common Stock · 1,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. Read SEC document
February 23, 2023 Filed Feb 28, 2023 02:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	1,107	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-013468 · doc4.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.